FDA — authorised 23 January 2020
- Application: NDA211723
- Marketing authorisation holder: EPIZYME INC
- Local brand name: TAZVERIK
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Tazverik in United States
FDA authorised Tazverik on 23 January 2020
Marketing authorisations
FDA — authorised 18 June 2020
- Application: NDA213400
- Marketing authorisation holder: EPIZYME INC
- Local brand name: TAZVERIK
- Indication: TABLET — ORAL
- Status: approved
FDA
- Status: approved
Tazverik in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Tazverik approved in United States?
Yes. FDA authorised it on 23 January 2020; FDA authorised it on 18 June 2020; FDA has authorised it.
Who is the marketing authorisation holder for Tazverik in United States?
EPIZYME INC holds the US marketing authorisation.